

§ 522.144

(pneumonia and strangles) due to *Staphylococcus* spp., *Streptococcus* spp. (including *S. equi*), *Escherichia coli*, and *Proteus mirabilis*, and skin and soft tissue infections (abscesses and wounds) due to *Staphylococcus* spp., *Streptococcus* spp., *E. coli*, and *P. mirabilis*, when caused by susceptible organisms.

(3) *Limitations*. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[72 FR 45158, Aug. 13, 2007, as amended at 79 FR 16184, Mar. 25, 2014]

§ 522.144 Arsenamide.

(a) *Specifications*. Each milliliter of solution contains 10.0 milligrams arsenamide sodium.

(b) *Sponsor*. See No. 050604 in § 510.600(c) of this chapter.

(c) *Conditions of use in dogs*—(1) *Amount*. Administer 0.1 milliliter (mL) per pound of body weight (1.0 mL for every 10 pounds) by intravenous injection twice a day for 2 days.

(2) *Indications for use*. For the treatment and prevention of canine heartworm disease caused by *Dirofilaria immitis*.

(3) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16184, Mar. 25, 2014]

§ 522.147 Atipamezole.

(a) *Specifications*. Each milliliter of solution contains 5.0 milligrams atipamezole hydrochloride.

(b) *Sponsor*. See No. 052483 in § 510.600(c) of this chapter.

(c) *Conditions of use in dogs*—(1) *Amount*. Inject intramuscularly the same volume as that of dexmedetomidine or medetomidine used.

(2) *Indications for use*. For reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride or medetomidine hydrochloride.

(3) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[61 FR 48830, Sept. 17, 1996, as amended at 64 FR 71640, Dec. 22, 1999; 72 FR 264, Jan. 4, 2007]

21 CFR Ch. I (4–1–14 Edition)

§ 522.150 Azaperone.

(a) *Specifications*. Each milliliter of solution contains 40 milligrams (mg) azaperone.

(b) *Sponsor*. See No. 000986 in § 510.600(c) of this chapter.

(c) *Conditions of use*—(1) *Indications for use*. For control of aggressiveness when mixing or regrouping weanling or feeder pigs weighing up to 80 pounds.

(2) *Dosage*. 2.2 mg per kilogram (1 mg per pound) by deep intramuscular injection.

(3) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[74 FR 65689, Dec. 11, 2009, as amended at 77 FR 46613, Aug. 6, 2012]

§ 522.161 Betamethasone.

(a) *Specifications*. Each milliliter of suspension contains:

(1) Betamethasone acetate equivalent to 10.8 milligrams (mg) betamethasone and betamethasone disodium phosphate equivalent to 3 mg of betamethasone.

(2) Betamethasone dipropionate equivalent to 5 mg betamethasone and betamethasone sodium phosphate equivalent to 2 mg of betamethasone.

(b) *Sponsor*. See sponsor numbers in § 510.600(c) of this chapter:

(1) No. 000061 for product described in paragraph (a)(1) of this section for use as in paragraphs (c)(1), (c)(2)(i), (c)(2)(ii)(A), and (c)(2)(iii) of this section.

(2) No. 000061 for product described in paragraph (a)(2) of this section for use as in paragraphs (c)(1), (c)(2)(i), (c)(2)(ii)(B), and (c)(2)(iii) of this section.

(c) *Conditions of use*—(1) *Dogs*—(i) *Amount*. Administer by intramuscular injection 0.25 to 0.5 milliliter (mL) per 20 pounds of body weight, depending on the severity of the condition. Frequency of dosage depends on recurrence of pruritic symptoms. Dosage may be repeated every 3 weeks or when symptoms recur, not to exceed a total of four injections.

(ii) *Indications for use*. As an aid in the control of pruritus associated with dermatoses.